(APLT) Applied Therapeutics - Ratings and Ratios

Applied Therapeutics, Inc. (NASDAQ: APLT) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for rare and debilitating diseases. The companys pipeline targets validated molecular pathways in indications with significant unmet medical needs, primarily in metabolic and diabetic complications. Its lead candidate, AT-007 (govorestat), is a small molecule inhibitor designed to address galactosemia, a rare genetic disorder affecting galactose metabolism. AT-007 has completed Phase 3 trials in healthy volunteers and adults and is currently in pediatric studies to evaluate its efficacy in children. Additionally, the compound is being investigated for enzyme deficiencies related to sorbitol dehydrogenase and phosphomannomutase-CDG.

The companys second lead candidate, AT-001 (caficrestat), is in Phase 3 clinical trials for diabetic cardiomyopathy and diabetic peripheral neuropathy. AT-001 aims to inhibit the enzyme aldose reductase, which plays a key role in the progression of diabetic complications. Preclinical studies are also underway for AT-003, a potential treatment for diabetic retinopathy. Applied Therapeutics has secured an exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize AT-007, enhancing its pathway to market.

Founded in 2016 and headquartered in New York, New York, the company operates in the biotechnology sector with a focus on rare metabolic disorders and diabetic complications. Its strategic approach emphasizes precision medicine and enzymatic targeting to develop therapies with high potential for clinical impact.